We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intuitive Surgical, Inc. (ISRG) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Intuitive Surgical, Inc. (ISRG - Free Report) closed at $1,036.52 in the latest trading session, marking a -0.55% move from the prior day. This change lagged the S&P 500's 0.88% gain on the day.
Prior to today's trading, shares of the company had gained 6.19% over the past month. This has outpaced the Medical sector's gain of 2.78% and the S&P 500's gain of 1.2% in that time.
ISRG will be looking to display strength as it nears its next earnings release. In that report, analysts expect ISRG to post earnings of $3.60 per share. This would mark year-over-year growth of 29.96%. Meanwhile, our latest consensus estimate is calling for revenue of $1.4 billion, up 29.88% from the prior-year quarter.
ISRG's full-year Zacks Consensus Estimates are calling for earnings of $14.80 per share and revenue of $5.65 billion. These results would represent year-over-year changes of +45.67% and +29.53%, respectively.
Investors might also notice recent changes to analyst estimates for ISRG. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. ISRG currently has a Zacks Rank of #2 (Buy).
Valuation is also important, so investors should note that ISRG has a Forward P/E ratio of 70.45 right now. This valuation marks a premium compared to its industry's average Forward P/E of 40.27.
Meanwhile, ISRG's PEG ratio is currently 7.29. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Instruments stocks are, on average, holding a PEG ratio of 3.29 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 173, which puts it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Intuitive Surgical, Inc. (ISRG) Stock Sinks As Market Gains: What You Should Know
Intuitive Surgical, Inc. (ISRG - Free Report) closed at $1,036.52 in the latest trading session, marking a -0.55% move from the prior day. This change lagged the S&P 500's 0.88% gain on the day.
Prior to today's trading, shares of the company had gained 6.19% over the past month. This has outpaced the Medical sector's gain of 2.78% and the S&P 500's gain of 1.2% in that time.
ISRG will be looking to display strength as it nears its next earnings release. In that report, analysts expect ISRG to post earnings of $3.60 per share. This would mark year-over-year growth of 29.96%. Meanwhile, our latest consensus estimate is calling for revenue of $1.4 billion, up 29.88% from the prior-year quarter.
ISRG's full-year Zacks Consensus Estimates are calling for earnings of $14.80 per share and revenue of $5.65 billion. These results would represent year-over-year changes of +45.67% and +29.53%, respectively.
Investors might also notice recent changes to analyst estimates for ISRG. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. ISRG currently has a Zacks Rank of #2 (Buy).
Valuation is also important, so investors should note that ISRG has a Forward P/E ratio of 70.45 right now. This valuation marks a premium compared to its industry's average Forward P/E of 40.27.
Meanwhile, ISRG's PEG ratio is currently 7.29. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Instruments stocks are, on average, holding a PEG ratio of 3.29 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 173, which puts it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.